How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience
Background. Hepatocellular carcinoma is a relevant cause of mortality worldwide, mainly among patients who have a prior liver disease. In spite of clear recommendations regarding surveillance and screening methods, most patients are still diagnosed only when they are no longer candidates to curative...
Saved in:
Main Authors: | Gustavo Hideki Kawanami, Leopoldo Katsuda, Thiara Barcelos Rocha, Fabio da Silva Yamashiro, Leonardo Pelafsky, Xingshun Qi, Fernando Gomes Romeiro |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Canadian Journal of Gastroenterology and Hepatology |
Online Access: | http://dx.doi.org/10.1155/2021/6219896 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of Electric Fields on the Mechanical Mechanism of Regorafenib–VEGFR2 Interaction to Enhance Inhibition of Hepatocellular Carcinoma
by: Yichen Tian, et al.
Published: (2025-01-01) -
Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
by: Finn RS, et al.
Published: (2025-02-01) -
CAR-T cell therapy in developing countries: how long should we wait?
by: Om P Kurmi, et al.
Published: (2024-12-01) -
Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials
by: Matt Vassar, et al.
Published: (2024-07-01) -
Improvement of the dissolution of the antineoplastic drug regorafenib through impregnation into pullulan polysaccharide using supercritical fluid technology: Optimization of the process
by: Ali Sheikhi, et al.
Published: (2025-03-01)